Titlebook: Diagnostic and Therapeutic Advances in Hematologic Malignancies; Martin S. Tallman,Leo I. Gordon Book 1999 Springer Science+Business Media

代替

丰满中国

,New classifications for non-Hodgkin’s lymphoma,f lymphoid neoplasia. At times, however, this complexity has been aggravated by variation in interobserver reliability . and by the use of different terms assigned by different investigators to describe biologically identical cell types or disease entities [.,.]

吝啬性

,Epstein—Barr virus and lymphoma,view aspects of the biology of the virus that are relevant to tumorigenesis, review the nature of the association with each of the tumors, and to consider therapeutic implications where these have been defined.

OVER

Current approaches to acute promyelocytic leukemia,17 ., younger age of onset ., and severe consumptive coagulopathy with a high incidence of early fatal hemorrhage [.,.]–.. This coagulopathy is frequently exacerbated by cytotoxic chemotherapy, probably a result of leukemia cell lysis with release of procoagulant intracellular contents [.,.].

拔出

低能儿

Hematopoietic growth factors and acute leukemia,ical application of cytokines in acute leukemia, and it is expected that this trend will continue over the next decade as further areas are explored and results of clinical trials mature to enable us to determine the precise role of cytokines in the clinical setting.

晚来的提名

achlorhydria

发微光

Mechanisms of resistance against B-cell malignancies induced by vaccination against the immunoglobuB-cell malignancies by active immunization. This chapter will summarize the progress in exploiting tumor-derived Ig protein as a tumor-specific antigen for therapeutic vaccine development and the priorities for future investigation.

extrovert

Novel biologic approaches to hematologic malignancies,kemia, this attempt has been quite successful, and in other situations we are still exploring the possibilities. Nevertheless, there appears to be a potential for growth control if not disease eradication through the utilization of biologic therapy in hematologic malignancies.